AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6806184 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 45% branched-chain amino acids (BCAAs)
Number of subjects: 30
Study 6806184 — intervention group
Group type: COMPARATOR
Intervention: Amino acid solution with 10% branched-chain amino acids (BCAAs)
Number of subjects: 30
Study 31913057 — intervention group
Group type: EXPERIMENTAL
Intervention: Count your drinks
Number of subjects: 2003
Study 31913057 — intervention group
Group type: EXPERIMENTAL
Intervention: Use a designated driver
Number of subjects: 2003
Study 31913057 — intervention group
Group type: EXPERIMENTAL
Intervention: Leave drinking venues at a pre‐determined time
Number of subjects: 2003
Study 31082943 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the prostate
Number of subjects: 0
Study 29145308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax AWS
Number of subjects: 140
Study 29145308 — intervention group
Group type: COMPARATOR
Intervention: McGrath VL
Number of subjects: 140
Study 25902324 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop anesthesia delivery system (CLADS)
Number of subjects: 242
Study 25902324 — intervention group
Group type: COMPARATOR
Intervention: Manual control (propofol infusion titrated manually)
Number of subjects: 242
Study 24399452 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 20 mg with ritonavir
Number of subjects: 0
Study 24399452 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg with ritonavir (simultaneous administration)
Number of subjects: 0
Study 24399452 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg with ritonavir (timed administration)
Number of subjects: 0
Study 24399452 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg with rifampicin
Number of subjects: 0
Study 21998118 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 365
Study 21998118 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus methotrexate
Number of subjects: 365
Study 18853093 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg od)
Number of subjects: 105
Study 18853093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 17176505 — intervention group
Group type: EXPERIMENTAL
Intervention: twice-daily rTMS (left prefrontal cortex, 10 Hz, 110% intensity, 1500 stimuli per session)
Number of subjects: 38
Study 17176505 — intervention group
Group type: EXPERIMENTAL
Intervention: once-daily rTMS
Number of subjects: 38
Study 17176505 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 38
Study 15867115 — intervention group
Group type: COMPARATOR
Intervention: Pediatric Asthma Care Intervention (PACI)
Number of subjects: 638
Study 15867115 — intervention group
Group type: COMPARATOR
Intervention: Peer Leader-based Physician Behavior Change Intervention (PLE)
Number of subjects: 638
Study 12197262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride 0.25% (n = 14)
Number of subjects: 22
Study 12197262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline injections; n = 8)
Number of subjects: 22
Study 10099042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Br)
Number of subjects: 8
Study 10099042 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MTC)
Number of subjects: 8
Study 10099042 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (DOMP)
Number of subjects: 8
Study 7813493 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin 3 x 10(6) U/6 h plus ofloxacin 200 mg twice daily (group A)
Number of subjects: 117
Study 7813493 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate 1 g/6 h plus erythromycin 1 g/8 h (group B)
Number of subjects: 117
Study 2667525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 3
Study 2667525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg/dihydroergotoxin 2 mg
Number of subjects: 3
Study 2667525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 409028 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen-only oral contraceptives
Number of subjects: 0
Study 409028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined progestogen-oestrogen oral contraceptives
Number of subjects: 0
Study 31838367 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support satisfaction
Number of subjects: 73
Study 31838367 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived competence in the ability to withdraw
Number of subjects: 73
Study 31838367 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 73
Study 31838367 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine intake factors (length of use and dose)
Number of subjects: 73
Study 31838367 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 73
Study 30874724 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (OAC plus aspirin and clopidogrel) for 4 weeks, followed by dual therapy (N)OAC plus clopidogrel until 12 months post-PCI, then (N)OAC monotherapy indefinitely.
Number of subjects: 47
Study 30874724 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of lower dose of NOAC in combination with antiplatelet(s) as per current recommendations.
Number of subjects: 47
Study 28129215 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic inverted ILM flap technique (Group 1)
Number of subjects: 81
Study 28129215 — intervention group
Group type: COMPARATOR
Intervention: Modified procedure with no extra flap manipulation (Group 2)
Number of subjects: 81
Study 28129215 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 81
Study 28129215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified inverted ILM technique
Number of subjects: 81
Study 25586810 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 256
Study 25586810 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 23782557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost, supportive footwear (Dr Comfort®, Vasyli Medical) in addition to usual DVA-subsidized podiatry care
Number of subjects: 120
Study 23782557 — intervention group
Group type: COMPARATOR
Intervention: Usual DVA-subsidized podiatry care without the footwear
Number of subjects: 120
Study 21385975 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope in left-lateral position
Number of subjects: 129
Study 21385975 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope in right-lateral position
Number of subjects: 129
Study 21385975 — intervention group
Group type: COMPARATOR
Intervention: Airway Scope in supine position
Number of subjects: 129
Study 17600848 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg)
Number of subjects: 57
Study 17600848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 16139810 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 52
Study 12658428 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal (TEP) repair
Number of subjects: 50
Study 12658428 — intervention group
Group type: COMPARATOR
Intervention: Open tension-free mesh Lichtenstein repair
Number of subjects: 50
Study 10842262 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear estimates of disease progression (LEP) based on grip or foot dorsiflexion (FD) strength and forced vital capacity (FVC%)
Number of subjects: 0
Study 10842262 — intervention group
Group type: EXPERIMENTAL
Intervention: LEP based on FD strength
Number of subjects: 0
Study 10842262 — intervention group
Group type: EXPERIMENTAL
Intervention: LEP based on FVC%
Number of subjects: 0
Study 10842262 — intervention group
Group type: EXPERIMENTAL
Intervention: LEP based on all measures
Number of subjects: 0
Study 8888417 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperformance behaviors (rituals) during golf putt, basketball free throw, and tennis serve.
Number of subjects: 7
Study 6359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 2,200 I.U./kg/hr
Number of subjects: 33
Study 6359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase 1,100 I.U./kg/hr
Number of subjects: 33
Study 6359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase initial dose of 250,000 I.U. followed by 100,000 I.U./hr
Number of subjects: 33
Study 6359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (both dosages)
Number of subjects: 33
Study 6359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 33
Study 6359570 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase treated patients
Number of subjects: 33
Study 30205667 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS)
Number of subjects: 91
Study 30205667 — intervention group
Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 91
Study 29336133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-colour sound generators (white, red, pink noise)
Number of subjects: 20
Study 29336133 — intervention group
Group type: COMPARATOR
Intervention: Conventional white noise sound generators
Number of subjects: 20
Study 27609525 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal psychodynamic therapy (FPT)
Number of subjects: 156
Study 27609525 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioural therapy (CBT-E)
Number of subjects: 156
Study 27609525 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU-O)
Number of subjects: 156
Study 25056510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy (steroid group)
Number of subjects: 259
Study 25056510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hydrocortisone)
Number of subjects: 259
Study 21955475 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 105
Study 21955475 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 19670560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position (LSP)
Number of subjects: 10
Study 19670560 — intervention group
Group type: COMPARATOR
Intervention: Supine position (SP)
Number of subjects: 10
Study 19670560 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LSP and SP
Number of subjects: 10
Study 17441877 — intervention group
Group type: EXPERIMENTAL
Intervention: Herculite XRV direct composite restorations
Number of subjects: 18
Study 15247722 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 50
Study 15247722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12198615 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 2418
Study 11705307 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin gel 0.1%
Number of subjects: 134
Study 11705307 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 134
Study 9440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (25 g)
Number of subjects: 520
Study 9440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (5 g)
Number of subjects: 520
Study 9440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (10 g)
Number of subjects: 520
Study 9440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 520
Study 9440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (25 g)
Number of subjects: 520
Study 8273381 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural bupivacaine (group 2)
Number of subjects: 10
Study 8273381 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (group 1)
Number of subjects: 10
Study 3687262 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux stomach replacement method
Number of subjects: 27
Study 3687262 — intervention group
Group type: COMPARATOR
Intervention: Longmire stomach replacement method
Number of subjects: 27
Study 3687262 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight and general condition
Number of subjects: 27
Study 29432650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic removal of fractured files from the middle third of root canals followed by instrumentation with the ProTaper Next (PTN) system.
Number of subjects: 18
Study 29432650 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Next (PTN) system instrumentation only (control group).
Number of subjects: 18
Study 28164639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 77
Study 28164639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexketoprofen
Number of subjects: 77
Study 28164639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol
Number of subjects: 77
Study 28164639 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 77
Study 24372612 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin-to-creatinine ratio
Number of subjects: 0
Study 24372612 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartiles of neopterin-to-creatinine ratio
Number of subjects: 0
Study 23271697 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated with 2-min bouts of light- or moderate-intensity treadmill walking every 20 min
Number of subjects: 8
Study 23271697 — intervention group
Group type: COMPARATOR
Intervention: Seated position with no activity
Number of subjects: 8
Study 20004371 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 104
Study 20004371 — intervention group
Group type: COMPARATOR
Intervention: Diet and aerobic exercise
Number of subjects: 104
Study 20004371 — intervention group
Group type: COMPARATOR
Intervention: Diet and combined aerobic-resistance exercise
Number of subjects: 104
Study 17712634 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli strain Nissle 1917 (EcN)
Number of subjects: 30
Study 17712634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16113846 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical myocardial revascularization (SMR)
Number of subjects: 96
Study 16113846 — intervention group
Group type: COMPARATOR
Intervention: Coronary angioplasty (TCA)
Number of subjects: 96
Study 12515745 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective nCPAP treatment
Number of subjects: 60
Study 12515745 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic nCPAP
Number of subjects: 60
Study 10500312 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) high-dose group (18,000 IU/kg, max 1.5 million IU)
Number of subjects: 556
Study 10500312 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) low-dose group (14,000 IU/kg, max 1 million IU)
Number of subjects: 556
Study 10500312 — intervention group
Group type: COMPARATOR
Intervention: Control group (heparin)
Number of subjects: 556
Study 8880557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination preparation (Diltiazem 150 mg / Hydrochlorothiazide 12.5 mg)
Number of subjects: 71
Study 8880557 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (150 mg)
Number of subjects: 71
Study 8880557 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg)
Number of subjects: 71
Study 1995100 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Fresh Whole Blood (VFWB)
Number of subjects: 161
Study 1995100 — intervention group
Group type: EXPERIMENTAL
Intervention: 24- to 48-hour-old Whole Blood
Number of subjects: 161
Study 1995100 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted Whole Blood (packed red blood cells, FFP, and platelets)
Number of subjects: 161
Study 1995100 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted Whole Blood
Number of subjects: 161
Study 30460353 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% NaHCO3 toothpaste
Number of subjects: 247
Study 30460353 — intervention group
Group type: COMPARATOR
Intervention: 0% NaHCO3 toothpaste
Number of subjects: 247
Study 27038114 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha neurofeedback training (NFT) with 8‐12‐Hz amplitude
Number of subjects: 50
Study 27038114 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving random 4‐Hz amplitude
Number of subjects: 50
Study 24374502 — intervention group
Group type: EXPERIMENTAL
Intervention: ORV-116E vaccine
Number of subjects: 0
Study 24374502 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of ORV-116E vaccine
Number of subjects: 0
Study 22842994 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ART (cART) for 72 weeks
Number of subjects: 0
Study 22842994 — intervention group
Group type: EXPERIMENTAL
Intervention: cART for 36 weeks followed by three ART-STIs
Number of subjects: 0
Study 22842994 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-STIs associated with pegylated interferon alpha-2b (peg-IFN) during the first 14 weeks
Number of subjects: 0
Study 22842994 — intervention group
Group type: COMPARATOR
Intervention: All regimens (cART, ART-STI, ART-STI-IFN)
Number of subjects: 0
Study 20542512 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA ethyl ester capsules
Number of subjects: 121
Study 20542512 — intervention group
Group type: COMPARATOR
Intervention: Control capsules
Number of subjects: 121
Study 19025504 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physiotherapy intervention (education, reassurance, pain management, mobility training, interferential therapy, walking training, and walking aids)
Number of subjects: 110
Study 19025504 — intervention group
Group type: COMPARATOR
Intervention: Control group (only walking training and walking aids)
Number of subjects: 110
Study 16271485 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtalar strapped insole (n=21)
Number of subjects: 42
Study 16271485 — intervention group
Group type: COMPARATOR
Intervention: Traditional shoe inserted wedged insole (n=21)
Number of subjects: 42
Study 14767409 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day for 1 week, then 3 g/day for 2 weeks)
Number of subjects: 26
Study 14767409 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 26
Study 11235060 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 0
Study 11235060 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9286467 — intervention group
Group type: EXPERIMENTAL
Intervention: Three meals per day
Number of subjects: 10
Study 9286467 — intervention group
Group type: COMPARATOR
Intervention: Eight meals per day
Number of subjects: 10
Study 8416077 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus presentation rate at 1.3 s ISI
Number of subjects: 0
Study 8416077 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus presentation rate at 2.1 s ISI
Number of subjects: 0
Study 8416077 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus presentation rate at 2.9 s ISI
Number of subjects: 0
Study 8416077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast and accurate choice responses to tones
Number of subjects: 0
Study 8416077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateralized readiness potential
Number of subjects: 0
Study 8416077 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 latency
Number of subjects: 0
Study 3516431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (600 mg/m2), methotrexate (40 mg/m2), 5‐fluorouracil (600 mg/m2) IV every 3 weeks and prednisone 20 mg/m2 PO daily, with diminishing doses (intermittent group)
Number of subjects: 100
Study 3516431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide (100 mg/m2 PO on days 1‐15, alternating with a 15‐day rest period), methotrexate 20 mg/m2 IV, 5‐fluorouracil 500 mg/m2 IV weekly for 20 weeks and prednisone 20 mg/m2 PO daily, with diminishing doses in the remission induction period, followed by a maintenance regimen (intensive group)
Number of subjects: 100
Study 3516431 — intervention group
Group type: COMPARATOR
Intervention: Intensive group
Number of subjects: 100
Study 3516431 — intervention group
Group type: COMPARATOR
Intervention: Intermittent group
Number of subjects: 100
Study 3516431 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study 31432535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning
Number of subjects: 1890
Study 30141230 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy with uniform scanning or pencil beam scanning, prescribed doses of 50.4‐66.4 Gy(RBE) scaled to 50.4 Gy(RBE) for analysis.
Number of subjects: 52
Study 27185621 — intervention group
Group type: EXPERIMENTAL
Intervention: Guy2Guy, a text messaging–based HIV prevention/healthy sexuality program
Number of subjects: 302
Study 25412862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (EdAl-2 programme)
Number of subjects: 690
Study 25412862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 690
Study 22963354 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored printed advice targeting health behaviours
Number of subjects: 2306
Study 22963354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2306
Study 20489580 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (5%) and Tobramycin (1.3%)
Number of subjects: 61
Study 20489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (0.3%)
Number of subjects: 61
Study 20489580 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (0.5%)
Number of subjects: 61
Study 18560218 — intervention group
Group type: EXPERIMENTAL
Intervention: rtPA thrombolysis
Number of subjects: 16
Study 18560218 — intervention group
Group type: COMPARATOR
Intervention: minor stroke (not receiving rtPA)
Number of subjects: 16
Study 15836828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment (100 kU intravenously drip, once every 8 hours for 5 days)
Number of subjects: 60
Study 15836828 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60
Study 15836828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment
Number of subjects: 60
Study 15836828 — intervention group
Group type: COMPARATOR
Intervention: Ulinastatin treatment and Routine treatment
Number of subjects: 60